in Asian and Other Diverse Communities
Expert Insight Into:
Risk and Predictors of Mortality Associated With Chronic Hepatitis B Infection
By Claire Sowerbutt
Expert Commentary by Adrian M. Di Bisceglie, MD, FACP
By Claire Sowerbutt
Expert Commentary by Adrian M. Di Bisceglie, MD, FACP
Click here to view our current activities in Gastroenterology.
This article review will help you identify prognostic factors, such as HBV DNA viral loads associated with mortality in high-risk populations, so as to facilitate better treatment of infected individuals and prevent progression to liver disease and hepatocellular carcinoma. Adrian M. Di Bisceglie, MD, FACP, provides expert commentary on the study findings. This is Course 14 of Advanced Certificate Program III: Bridging Cultural Differences to Improve HBV Treatment in Asian and Other Diverse Communities.
Adrian M. Di Bisceglie, MD, FACP
- Acting Chairman, Internal Medicine
- Chief of Hepatology
- Saint Louis University School of Medicine
- St. Louis, Missouri
Robert G. Gish, MD, has received grant/research support from Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb, Gilead Sciences, Inc, Hoffmann-La Roche Inc, Idenix Pharmaceuticals Inc, InterMune Inc, Ortho Biotech Products, LP, Pfizer, Inc, Schering-Plough Corporation, SciClone Pharmaceuticals, and Valeant Pharmaceuticals International; is a consultant for Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb, Chiron Corporation, Corixa Corporation, Gilead Sciences, Inc, GlaxoSmithKline, HepaHope, Inc, Hoffmann-La Roche Inc, Human Genome Sciences, Idenix Pharmaceuticals Inc, InterMune Pharmaceuticals, Inc, Metabasis Therapeutics, Inc, Ortho Biotech Products, LP, Pharmasset Pharmaceuticals Inc, Schering-Plough Corporation, SciClone Pharmaceuticals, Valeant Pharmaceuticals International, and ZymoGenetics, Inc; and is on the speakers bureau of Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Hoffmann-La Roche Inc, Schering-Plough Corporation, and Three Rivers Pharmaceuticals International.
W. Ray Kim, MD, has received grant/research support from Gilead Sciences, Inc; is a consultant for and is on the advisory boards of Bristol-Myers Squibb, Gilead Sciences, Inc, Roche Pharmaceuticals, and Schering-Plough Corporation.
George KK Lau, MD, has no significant relationships to disclose.
Mindie Nguyen, MD, MAS, has received grant/research support from Gilead Sciences, Inc, Idenix Pharmaceuticals, Novartis Pharmaceuticals Corporation, and Roche Pharmaceuticals; and is on the speakers bureau of and is a member of advisory boards for Bristol-Myers Squibb, Gilead Sciences, Inc, and Idenix/Novartis.
Available for CME/CE:
Physicians
Publish Date: Mar 18, 2008 Termination Date: Mar 18, 2009Nurses
Publish Date: Mar 18, 2008 Termination Date: Mar 18, 2009Estimated time for completion of this activity:
CNE: 30.00 minutes
Target Audience
This activity is designed for gastroenterologists, hepatologists, and other clinicians who care for patients with hepatitis B infection or those at increased risk for acquiring the infection.
Activity Goal
The goal of this CME/CE activity is to examine the latest information about treating chronic hepatitis B virus (HBV) infection, taking into account the most current guidelines, recent FDA approvals, and new data, in order to effectively suppress viral replication.
Learning Objective (s)
- Integrate knowledge of current and emerging strategies in screening, diagnosis, and treatment options into clinical practice, to improve the outcomes of patients with HBV.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
This program has been approved by the American Association of Critical-Care Nurses (AACN) for 0.50 contact hour(s). Provider #00013784.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Adrian M. Di Bisceglie, MD, FACP has received grant/research support from Bristol-Myers Squibb Company, Gilead Sciences, Inc, Idenix Pharmaceuticals, Roche Pharmaceuticals, SciClone Pharmaceuticals, and Vertex Pharmaceuticals Inc; is a consultant for Abbott Laboratories, Bristol-Myers Squibb Company, Pharmasset Pharmaceuticals, Inc, Schering-Plough Corporation, and SciClone Pharmaceuticals; is on the speakers bureau of Bristol-Myers Squibb Company, Gilead Sciences, Inc, and Roche Pharmaceuticals; and is a member of advisory boards for Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb Company, GlobeImmune, Inc, Idenix Pharmaceuticals, Inc, Metabasis Therapeutics, Novartis Pharmaceuticals Corporation, Roche Pharmaceuticals, and Vertex Pharmaceuticals Incorporated.
Peer Reviewer has disclosed no significant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.
Claire Sowerbutt has disclosed no significant relationships.
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Adrian M. Di Bisceglie, MD, FACP has received grant/research support from Bristol-Myers Squibb, Gilead Sciences, Inc, GlobeImmune, Inc, Idenix Pharmaceuticals, Pharmasset Pharmaceuticals Inc, Roche Pharmaceuticals, SciClone Pharmaceuticals, and Vertex Pharmaceuticals Inc; is a consultant for Abbott Laboratories, Bristol-Myers Squibb, Pharmasset Pharmaceuticals Inc, Schering-Plough Corporation, and SciClone Pharmaceuticals; is on the speakers bureau of Bristol-Myers Squibb and Novartis Pharmaceuticals Corporation; and is a member of advisory boards for Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb, GlobeImmune, Inc, Idenix Pharmaceuticals, Inc, Metabasis Therapeutics, Novartis Pharmaceuticals Corporation, Roche Pharmaceuticals, and Vertex Pharmaceuticals Incorporated.
Robert G. Gish, MD has received grant/research support from Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb, Gilead Sciences, Inc, Hoffmann-La Roche Inc, Idenix Pharmaceuticals Inc, InterMune Inc, Ortho Biotech Products, LP, Pfizer, Inc, Schering-Plough Corporation, SciClone Pharmaceuticals, and Valeant Pharmaceuticals International; is a consultant for Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb, Chiron Corporation, Corixa Corporation, Gilead Sciences, Inc, GlaxoSmithKline, HepaHope, Inc, Hoffmann-La Roche Inc, Human Genome Sciences, Idenix Pharmaceuticals Inc, InterMune Pharmaceuticals, Inc, Metabasis Therapeutics, Inc, Ortho Biotech Products, LP, Pharmasset Pharmaceuticals Inc, Schering-Plough Corporation, SciClone Pharmaceuticals, Valeant Pharmaceuticals International, and ZymoGenetics, Inc; and is on the speakers bureau of Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Hoffmann-La Roche Inc, Schering-Plough Corporation, and Three Rivers Pharmaceuticals International.
W. Ray Kim, MD has received grant/research support from Gilead Sciences, Inc; is a consultant for and is on the advisory boards of Bristol-Myers Squibb, Gilead Sciences, Inc, Roche Pharmaceuticals, and Schering-Plough Corporation.
George KK Lau, MD has no significant relationships to disclose.
Mindie Nguyen, MD, MAS has received grant/research support from Gilead Sciences, Inc, Idenix Pharmaceuticals, Novartis Pharmaceuticals Corporation, and Roche Pharmaceuticals; and is on the speakers bureau of and is a member of advisory boards for Bristol-Myers Squibb, Gilead Sciences, Inc, and Idenix/Novartis.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
Available for CME/CE:
Physicians
Publish Date: Mar 18, 2008 Termination Date: Mar 18, 2009Nurses
Publish Date: Mar 18, 2008 Termination Date: Mar 18, 2009Estimated time for completion of this activity:
CNE: 30.00 minutes
Target Audience
This activity is designed for gastroenterologists, hepatologists, and other clinicians who care for patients with hepatitis B infection or those at increased risk for acquiring the infection.
Activity Goal
The goal of this CME/CE activity is to examine the latest information about treating chronic hepatitis B virus (HBV) infection, taking into account the most current guidelines, recent FDA approvals, and new data, in order to effectively suppress viral replication.
Learning Objective (s)
- Integrate knowledge of current and emerging strategies in screening, diagnosis, and treatment options into clinical practice, to improve the outcomes of patients with HBV.
CME Information: Physicians
Statement of Accreditation
Projects In Knowledge® is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation
Projects In Knowledge® designates this educational activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CE Information: Nurses
This program has been approved by the American Association of Critical-Care Nurses (AACN) for 0.50 contact hour(s). Provider #00013784.
CME/CE Instructions
To obtain CME/CE credit:
- Read or listen to each activity carefully.
- Complete/submit each posttest and evaluation.
- Instantly access and print out your certificate.
There is no fee for this activity.
Projects In Knowledge has developed the contract to demonstrate our commitment to providing the highest quality professional education to clinicians, and to help clinicians set educational goals to challenge and enhance their learning experience.
For more information on the contract, click here.
The Disclosure Policy of Projects In Knowledge® requires that presenters comply with the Standards for Commercial Support. All faculty are required to disclose any personal interest or relationship they or their spouse/partner have with the supporters of this activity or any commercial interest that is discussed in their presentation. Any discussions of unlabeled/unapproved uses of drugs or devices will also be disclosed in the course materials.
For complete prescribing information on the products discussed during this CME/CE activity, please see your current Physicians' Desk Reference (PDR).
Adrian M. Di Bisceglie, MD, FACP has received grant/research support from Bristol-Myers Squibb Company, Gilead Sciences, Inc, Idenix Pharmaceuticals, Roche Pharmaceuticals, SciClone Pharmaceuticals, and Vertex Pharmaceuticals Inc; is a consultant for Abbott Laboratories, Bristol-Myers Squibb Company, Pharmasset Pharmaceuticals, Inc, Schering-Plough Corporation, and SciClone Pharmaceuticals; is on the speakers bureau of Bristol-Myers Squibb Company, Gilead Sciences, Inc, and Roche Pharmaceuticals; and is a member of advisory boards for Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb Company, GlobeImmune, Inc, Idenix Pharmaceuticals, Inc, Metabasis Therapeutics, Novartis Pharmaceuticals Corporation, Roche Pharmaceuticals, and Vertex Pharmaceuticals Incorporated.
Peer Reviewer has disclosed no significant relationships.
Dorothy Caputo, MA, BSN, RN (lead nurse planner) has no significant relationships to disclose.
Bernadette Marie Makar, MSN, NP-C, APRN-C (nurse planner) has no significant relationships to disclose.
Claire Sowerbutt has disclosed no significant relationships.
Projects In Knowledge's staff members have no significant relationships to disclose.
Planning Committee
Adrian M. Di Bisceglie, MD, FACP has received grant/research support from Bristol-Myers Squibb, Gilead Sciences, Inc, GlobeImmune, Inc, Idenix Pharmaceuticals, Pharmasset Pharmaceuticals Inc, Roche Pharmaceuticals, SciClone Pharmaceuticals, and Vertex Pharmaceuticals Inc; is a consultant for Abbott Laboratories, Bristol-Myers Squibb, Pharmasset Pharmaceuticals Inc, Schering-Plough Corporation, and SciClone Pharmaceuticals; is on the speakers bureau of Bristol-Myers Squibb and Novartis Pharmaceuticals Corporation; and is a member of advisory boards for Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb, GlobeImmune, Inc, Idenix Pharmaceuticals, Inc, Metabasis Therapeutics, Novartis Pharmaceuticals Corporation, Roche Pharmaceuticals, and Vertex Pharmaceuticals Incorporated.
Robert G. Gish, MD has received grant/research support from Bayer Pharmaceuticals Corporation, Bristol-Myers Squibb, Gilead Sciences, Inc, Hoffmann-La Roche Inc, Idenix Pharmaceuticals Inc, InterMune Inc, Ortho Biotech Products, LP, Pfizer, Inc, Schering-Plough Corporation, SciClone Pharmaceuticals, and Valeant Pharmaceuticals International; is a consultant for Anadys Pharmaceuticals, Inc, Bristol-Myers Squibb, Chiron Corporation, Corixa Corporation, Gilead Sciences, Inc, GlaxoSmithKline, HepaHope, Inc, Hoffmann-La Roche Inc, Human Genome Sciences, Idenix Pharmaceuticals Inc, InterMune Pharmaceuticals, Inc, Metabasis Therapeutics, Inc, Ortho Biotech Products, LP, Pharmasset Pharmaceuticals Inc, Schering-Plough Corporation, SciClone Pharmaceuticals, Valeant Pharmaceuticals International, and ZymoGenetics, Inc; and is on the speakers bureau of Bristol-Myers Squibb, Gilead Sciences, Inc, GlaxoSmithKline, Hoffmann-La Roche Inc, Schering-Plough Corporation, and Three Rivers Pharmaceuticals International.
W. Ray Kim, MD has received grant/research support from Gilead Sciences, Inc; is a consultant for and is on the advisory boards of Bristol-Myers Squibb, Gilead Sciences, Inc, Roche Pharmaceuticals, and Schering-Plough Corporation.
George KK Lau, MD has no significant relationships to disclose.
Mindie Nguyen, MD, MAS has received grant/research support from Gilead Sciences, Inc, Idenix Pharmaceuticals, Novartis Pharmaceuticals Corporation, and Roche Pharmaceuticals; and is on the speakers bureau of and is a member of advisory boards for Bristol-Myers Squibb, Gilead Sciences, Inc, and Idenix/Novartis.
Conflicts of interest are thoroughly vetted by the Executive Committee of Projects In Knowledge. All conflicts are resolved prior to the beginning of the activity by the Trust In Knowledge peer review process.
The opinions expressed in this activity are those of the faculty and do not necessarily reflect those of Projects In Knowledge.
This CME/CE activity is provided solely as an educational service. Specific patient care decisions are the responsibility of the clinician caring for the patient.
Projects In Knowledge is a registered trademark of Projects In Knowledge, Inc.
|



